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Effect of Rosuvastatin on Acute  
Kidney Injury in Sepsis-Associated  
Acute Respiratory Distress Syndrome
Raymond K. Hsu1 , Jonathon D. Truwit2,  
Michael A. Matthay3,4, Joseph E. Levitt5,  
Boyd Taylor Thompson6,7, and Kathleen D. Liu1,3
Abstract
Background: Acute kidney injury (AKI) commonly occurs in patients with sepsis and acute respiratory distress syndrome 
(ARDS).
Objective: To investigate whether statin treatment is protective against AKI in sepsis-associated ARDS.
Design: Secondary analysis of data from Statins for Acutely Injured Lungs in Sepsis (SAILS), a randomized controlled trial 
that tested the impact of rosuvastatin therapy on mortality in patients with sepsis-associated ARDS.
Setting: 44 hospitals in the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network.
Patients: 644 of 745 participants in SAILS who had available baseline serum creatinine data and who were not on chronic 
dialysis.
Measurements: Our primary outcome was AKI defined using the Kidney Disease Improving Global Outcomes creatinine 
criteria. Randomization to rosuvastatin vs placebo was the primary predictor. Additional covariates include demographics, 
ARDS etiology, and severity of illness.
Methods: We used multivariable logistic regression to analyze AKI outcomes in 511 individuals without AKI at randomization, 
and 93 with stage 1 AKI at randomization.
Results: Among individuals without AKI at randomization, rosuvastatin treatment did not change the risk of AKI (adjusted 
odds ratio: 0.99, 95% confidence interval [CI]: 0.67-1.44). Among those with preexisting stage 1 AKI, rosuvastatin treatment 
was associated with an increased risk of worsening AKI (adjusted odds ratio: 3.06, 95% CI: 1.14-8.22). When serum creatinine 
was adjusted for cumulative fluid balance among those with preexisting stage 1 AKI, rosuvastatin was no longer associated 
worsening AKI (adjusted odds ratio: 1.85, 95% CI: 0.70-4.84).
Limitations: Sample size, lack of urine output data, and prehospitalization baseline creatinine.
Conclusion: Treatment with rosuvastatin in patients with sepsis-associated ARDS did not protect against de novo AKI or 
worsening of preexisting AKI.
Abrégé 
Contexte: L’insuffisance rénale aiguë (IRA) survient fréquemment chez les patients atteints d’une septicémie et du syndrome 
de détresse respiratoire aiguë (SDRA).
Objectif de l’étude: Déterminer si un traitement aux statines offre une protection contre l’IRA chez les patients atteints 
d’un SDRA associé à une septicémie.
Type d’étude: Il s’agit d’une analyse secondaire des données de l’étude SAILS (Statins for Acutely Injured Lungs in Sepsis), un 
essai contrôlé à répartition aléatoire qui se penchait sur l’effet d’un traitement à la rosuvastatine sur le taux de mortalité des 
patients atteints d’un SDRA associé à une septicémie.
Cadre de l’étude: Les données proviennent de 44 centres hospitaliers du réseau National Heart, Lung, and Blood Institute 
ARDS Clinical Trials Network.
Patients: Les 644 participants à l’essai SAILS (sur un total de 745) non dialysés à vie et pour qui on disposait de valeurs 
initiales de créatinine sérique.
Mesures: La principale mesure observée était une atteinte d’IRA, définie selon les critères liés aux valeurs de la créatinine 
avancées par la fondation Kidney Disease : Improving Global Outcomes. Le facteur prédictif essentiel était la répartition aléatoire 
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des sujets (traitement à la rosuvastatine ou par placébo). Les caractéristiques sociodémographiques des patients, l’étiologie 
du SDRA et la gravité de l’atteinte constituaient les covariables additionnelles colligées.
Méthodologie: La survenue d’une IRA a été analysée par régression logistique multivariée chez deux sous-groupes : 511 
patients qui ne présentaient initialement aucun signe clinique d’IRA et 93 patients initialement atteints d’IRA de stade 1.
Résultats: Chez les sujets non atteints d’IRA au moment de la répartition, le traitement à la rosuvastatine n’a eu aucun effet 
sur le risque de survenue d’IRA (rapport de cotes corrigé : 0,99; IC 95 % : 0,67-1,44). Chez les sujets initialement atteints 
d’IRA de stade 1, le traitement à la rosuvastatine a été associé à un risque plus élevé d’aggravation de l’atteinte existante 
(rapport de cotes corrigé : 3,06; IC 95 % : 1,14-8,22). Cependant, chez ces mêmes sujets, lorsque la créatinine sérique a été 
ajustée selon le bilan hydrique cumulatif, l’effet néfaste de la rosuvastatine n’a plus été observé (rapport de cotes corrigé : 
1,85; IC 95 % : 0,70-4,84).
Limites: La taille de l’échantillon ainsi que l’absence de certaines données (concernant notamment la créatinine 
préhospitalisation et la diurèse) limitent les constats de notre étude.
Conclusion: Un traitement par rosuvastatine n’a eu aucun effet protecteur contre le développement ou l’aggravation d’une 
IRA chez des patients atteints du SDRA associé à une septicémie.
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What was known before
Statins have been shown to prevent septic and ischemic acute 
kidney injury (AKI) in some animal models, and recent 
human data—including randomized trials—suggest poten-
tial benefit in prevention of contrast-induced AKI. However, 
it is not known whether statin therapy may be protective 
against sepsis-associated AKI in critically ill patients with 
acute respiratory distress syndrome (ARDS).
What this adds
Using data from Statins for Acutely Injured Lungs in Sepsis 
(SAILS), we found that administration of rosuvastatin did 
not prevent new-onset AKI and did not prevent worsening of 
existing AKI, after taking into account demographics, ARDS 
etiology, and severity of illness.
Introduction
Acute kidney injury (AKI) is a common and serious compli-
cation in patients with sepsis. Among critically ill patients, 
sepsis is estimated to be the primary trigger for ~40% to 
50% of AKI cases.1 Sepsis-associated AKI is associated 
with mortality of up to 50% to 60%, with a graded associa-
tion between AKI severity and death.2 There are limited 
therapeutic options in treating sepsis-associated AKI besides 
supportive care, including renal replacement therapies when 
indicated.
Statins have been shown to prevent septic and ischemic 
AKI in mouse models3-5 and have been proposed as a novel 
treatment for AKI. Recent human studies have primarily 
focused on the effect of statin therapy on preventing AKI in 
patients undergoing coronary angiography6 and cardiac sur-
gery.7 In this study, we sought to investigate the effect of 
statin therapy on sepsis-associated AKI in critically ill patients 
with the acute respiratory distress syndrome (ARDS).
Methods
Study Design and Population
We analyzed data from the Statins for Acutely Injured Lungs 
in Sepsis (SAILS) study from the National Heart, Lung, 
and Blood Institute ARDS Clinical Trials Network.8 SAILS 
was a multicenter, prospective, randomized controlled, 
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double-blinded trial evaluating the effect of rosuvastatin 
therapy in critically ill patients with sepsis-associated ARDS. 
In total, 745 participants were enrolled from 44 hospitals 
from 2010 to 2013. The original SAILS design, protocol, and 
primary results have been described and published.8 Patients 
were eligible if they were receiving mechanical ventilation 
meeting the American/European Consensus Conference def-
inition for Acute Lung Injury9 and had evidence of a known 
or suspected infection at study entry. Patients were random-
ized to placebo vs rosuvastatin 40 mg at the time of enroll-
ment followed by 20 mg daily until the third day after 
intensive care unit discharge, study day 28, hospital dis-
charge, or death. Rosuvastatin dose was reduced to 10 mg for 
patients with creatinine level ≥2.8 mg/dL (while not on dial-
ysis). The primary predictor for the current analysis is rosuv-
astatin treatment as specified in the original trial in an 
intention-to-treat design.
The institutional review boards at each participating insti-
tution reviewed and approved the study protocol; informed 
consent was obtained from all patients or their health care 
surrogates.
Main Analysis
For the present analysis, we excluded 15 patients who were 
on chronic dialysis prior to the study and 86 patients with a 
missing creatinine measurement in the first 7 days after ran-
domization. The remaining population was divided into 
those without AKI at the time of randomization and those 
with preexisting AKI at the time of randomization. AKI was 
defined using the Kidney Disease Improving Global 
Outcomes (KDIGO) creatinine-based criteria.10 The primary 
outcome for those without AKI at randomization was the 
development of de novo AKI within 7 days after randomiza-
tion. De novo AKI is defined as an increase in creatinine by 
≥0.3 mg/dL within 48 hours or an increase of creatinine by 
≥50% from baseline over the first 7 days (with baseline cre-
atinine defined as the lowest creatinine within 96 hours prior 
to randomization). The primary outcome for those with pre-
existing stage 1 AKI was the development of worsening 
(stage 2 or 3) AKI stage, including receipt of dialysis. 
Participants with preexisting stage 2/3 AKI were not included 
in regression analyses. Figure 1 illustrates the derivation of 
our analytic cohort.
We used multivariable logistic regression to determine the 
association between rosuvastatin and AKI outcomes. We a 
priori decided to adjust for age, sex, race, ethnicity, ARDS 
etiology (primary respiratory defined as pneumonia or aspi-
ration, vs nonrespiratory etiology), and severity of illness 
defined using Acute Physiology, Age, Chronic Health 
Evaluation (APACHE) III scores.
We additionally performed exploratory analysis com-
paring peak serum creatine kinase (CK) levels between 
rosuvastatin and control groups, separately for those with 
and without preexisting AKI. The incidence of serum CK 
levels above 10 times the upper limit of normal were also 
compared between rosuvastatin and control groups, to mirror 
analysis performed in the original SAILS publication.8
All data were prospectively collected during the original 
trial. Analysis was conducted using STATA 14.1/SE (College 
Station, Texas).
Fluid-Adjusted Analysis
Prior data from the ARDS Network have shown that fluid 
balance can confound AKI ascertainment.11 Correction of 
creatinine for fluid balance may reassign patients from 
AKI to non-AKI groups and vice versa. Therefore, we rep-
licated previously published methodology11,12 to adjust 
serum creatinine for volume of distribution. We first esti-
mated the volume of distribution for creatinine on the day 
of randomization as the total body water (TBW), equaling 
60% of body weight on randomization.13 We then calcu-
lated the on-study cumulative fluid balance using 24-hour 
fluid intake/output recorded. The final fluid-adjusted cre-
atinine11 is equal to the measured creatinine × (1 + [on-
study cumulative fluid balance/TBW]). Patients are then 
reclassified as AKI or no AKI using fluid-adjusted creati-
nines, and the primary analysis was repeated using these 
fluid-adjusted values.
Results
Among 644 participants in our analytic cohort, 511 (79%) 
had no AKI, 93 (14%) had stage 1 AKI, and 40 (6%) had 
stage 2 or stage 3 AKI before randomization (Figure 1). Our 
cohort had similar characteristics as the original trial partici-
pants (Table 1). The median age was 55 (interquartile range 
[IQR]: 42-66), 51% were female, 14% were African 
American, and 12% were of Hispanic ethnicity. Mean base-
line creatinine for both rosuvastatin and placebo groups were 
1.2 mg/dL.
Effect of Rosuvastatin on De Novo AKI
Among the 511 participants without preexisting AKI at ran-
domization, 200 (39%) developed stage 1 or greater AKI 
after randomization. There were no significant differences in 
risk of AKI between the rosuvastatin and control groups. 
Further analysis using fluid-adjusted creatinines to ascertain 
AKI also showed no difference in AKI risk between the rosu-
vastatin and control groups (Table 2).
Effect of Rosuvastatin on Preexisting Stage 1 AKI
Among the 93 participants with preexisting stage 1 AKI at 
randomization, 49 (53%) progressed to stage 2 or higher AKI 
after randomization (Table 2). In our primary analysis, the 
rosuvastatin group had a 3-fold higher adjusted odds of 
worsening AKI (P = .03). However, this association was no 
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longer significant in our secondary analysis when creatinine 
levels were adjusted for fluid balance (adjusted odds ratio: 
1.85, 95% confidence interval [CI]: 0.70-4.84, P = .21). We 
found that there was a trend toward higher prevalence of 
vasopressor use before randomization in the placebo group 
(81%) compared with the rosuvastatin group (62%, P = .06) 
which was associated with higher mean fluid balance at ran-
domization (+ 4.3 L in the placebo group vs + 2.5 L in the 
rosuvastatin group, P = .02).
Serum CK Levels
Table 3 shows the baseline and peak serum CK levels by 
subgroups and by placebo vs rosuvastatin treatment. 
Notably, among patients with preexisting stage 1 AKI at 
randomization, there was higher crude incidence of peak 
CK above 10 times the upper limit of normal for those 
treated with rosuvastatin (20%) vs those treated with pla-
cebo (8%; P = .09).
Discussion
In this analysis of patients with sepsis-associated ARDS 
enrolled in a randomized clinical trial, we found that rosuv-
astatin treatment did not protect against de novo AKI or 
worsening of existing mild AKI. To our knowledge, this is 
the first study to examine the effect of statin therapy in sep-
sis-associated AKI in humans. Our study adds to an emerg-
ing body of literature exploring whether statins may offer a 
renoprotective benefits.
Statins are potent lipid-lowering agents that are effective 
in preventing and treating coronary artery disease. The 
potentially nephroprotective effect of statin therapy is rooted 
in the “pleiotropic” effects including enhancement of nitric 
oxide production along with anti-inflammatory and antioxi-
dant properties.14 Yet the benefits of statins on kidney disease 
remain controversial. A recent meta-analysis of more than 50 
randomized controlled trials (RCTs) in which statins were 
given for at least 6 months concluded that statin therapy did 
Figure 1. Screening, randomization, and derivation of analytic cohort.
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not reduce the risk for kidney failure events (defined as end-
stage renal disease, doubling of serum creatinine, or >25% or 
50% decrease in estimated glomerular filtration rate [eGFR] 
depending on the study) among adults not already receiving 
Table 1. Baseline Characteristics of Study Participants.
Prerandomization characteristics All (n = 644) Placebo (n = 315) Rosuvastatin (n = 329) P
Age 54.2 (16.4) 54.1 (15.8) 54.4 (17.0) .82
 Median (IQR) 55 (42-66) 55 (43-65) 55 (42-67)  
Female 329 (51%) 164 (52%) 165 (50%) .63
Race .68
 White 515 (80%) 254 (81%) 261 (79%)  
 African American 88 (14%) 42 (13%) 46 (14%)  
 Other 20 (3%) 10 (3%) 10 (3%)  
 Unknown 21 (3%) 9 (3%) 12 (4%)  
Hispanic ethnicity 76 (12%) 34 (11%) 42 (13%) .77
Weight (kg) 87.7 (30.9) 86.6 (31.3) 88.8 (30.5) .39
 Median (IQR) 82 (68-100) 80 (66-100) 84 (69-100)  
ARDS etiology  
 Direct (pneumonia or aspiration) 509 (79%) 247 (78%) 262 (80%) .43
APACHE III score (n = 613) 93.2 (27.8) 94.7 (27.1) 91.7 (28.4) .18
Baseline creatinine (mg/dL) (n = 640) 1.2 (0.9) 1.2 (0.9) 1.2 (0.9) .62
 Median (IQR) 0.9 (0.7-1.4) 1.0 (0.6-1.5) 0.9 (0.7-1.4)  
AKI before randomization 133 (20%) 58 (18%) 75 (23%) .17
 AKI requiring dialysis 37 (6%) 20 (6%) 17 (5%) .52
Note. IQR = interquartile range; ARDS = acute respiratory distress syndrome; AKI = acute kidney injury
Table 2. Effect of Rosuvastatin on Acute Kidney Injury Outcomes.
Outcome: de novo AKI in patients 
without preexisting AKI (n = 511) Placebo (n = 257) Rosuvastatin (n = 254) P
Developed AKI 103 (40%) 97 (38%) .66
 Stage 1 (% out of all AKI) 44 (42.7%) 34 (35.1%)  
 Stage 2 11 (10.7%) 12 (12.4%)  
 Stage 3 without dialysis 32 (31.1%) 35 (36.1%)  
 Stage 3 with dialysis 16 (15.5%) 16 (16.5%)  
Logistic regression analysis OR (95% CI)  
 Crude Reference 0.92 (0.65-1.32) .66
 Multivariablea Reference 0.99 (0.67-1.44) .94
Fluid-adjusted analysis OR (95% CI)  
 Crude Reference 0.84 (0.59-1.21) .35
 Multivariablea Reference 0.92 (0.63-1.34) .64
Outcome: worsened AKI in patients 
with preexisting stage 1 AKI (n = 93) Placebo (n = 39) Rosuvastatin (n = 54) P
Developed ≥ stage 2 AKI post 
randomization
16 (41%) 33 (61%) .06
Logistic regression analysis OR (95% CI)  
 Crude Reference 2.26 (0.97-5.24) .06
 Multivariablea Reference 3.06 (1.14-8.22) .03
Fluid-adjusted analysis OR (95% CI)  
 Crude Reference 1.41 (0.61-3.27) .42
 Multivariablea Reference 1.85 (0.70-4.84) .21
Note. AKI = acute kidney injury; OR = odds ratio; CI = confidence interval.
aMultivariable analyses were adjusted for age, sex, race, ethnicity, ARDS etiology (primary respiratory etiology defined as either pneumonia or aspiration, 
vs nonrespiratory etiology), and severity of illness defined by APACHE III scores.
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dialysis, but that statin therapy may modestly reduce protein-
uria and rate of eGFR decline.15
The potential role of short-term statin administration on 
AKI prevention has been investigated more recently in 
human studies. Several recent RCTs found that short-term 
precontrast statin administration may be protective against 
contrast-associated AKI (CA-AKI).6,16-18 The largest of these 
studies randomized nearly 3000 patients in China with type 
2 diabetes or mild to moderate chronic kidney disease under-
going coronary or peripheral arterial angiography to a 5-day 
course of rosuvastatin vs no statin and found the incidence of 
CA-AKI to be significantly lower in the rosuvastatin group 
(2.3% vs 3.9%, P = .01).16 However, more studies are needed 
to replicate the effect sizes seen in recent studies and to 
determine the best groups to target for CA-AKI. In the car-
diac surgery setting, recent large RCTs found that statin 
administration did not protect against postoperative AKI,7,19 
while a possibility of renal harm was suggested by some 
data.7,20
Our analysis did not demonstrate any renal benefit with 
rosuvastatin in patients with sepsis and ARDS. Rather, our 
primary analysis showed that rosuvastatin treatment may in 
fact be harmful in patients with preexisting AKI, though this 
finding may be confounded by prerandomization differences 
in fluid balance and vasopressor use between the groups. We 
had only a modest number of patients with preexisting AKI 
at randomization, which limited our power to detect potential 
harm or benefit. In the original SAILS study, enrollment was 
stopped early due to futility after 745 participants (out of 
planned 1000) for lack of benefit with regard to in-hospital 
mortality.8 Interestingly, in the original SAILS study, the 
rosuvastatin group had slightly fewer days free of renal fail-
ure (mean 10.1 days in the rosuvastatin arm vs 11.0 days in 
placebo arm, P = .01).8 However, renal failure was defined 
fairly crudely as serum creatinine level of at least 2.0 mg/dL 
in the original study, while our current analysis used a more 
updated consensus definition of AKI and incorporated both 
de novo AKI as well as worsening serum creatinine in those 
with preexisting AKI as outcomes. Therefore, we believe 
that a potentially detrimental renal effect of rosuvastatin—in 
the setting of sepsis—cannot be ruled out.
The mechanism for possible deleterious renal effect of 
statins is unclear. As the kidneys are responsible for excret-
ing 10% of rosuvastatin (vs 90% eliminated in feces),21 it is 
plausible that patients with preexisting AKI were at higher 
risk of any potentially nephrotoxic effect due to higher circu-
lating levels of rosuvastatin. AKI associated with statin 
administration is most commonly caused by rhabdomyolysis 
leading to acute tubular necrosis (often in the setting of con-
current use of fibrates or other interacting medications, 
which were exclusion criteria in the original SAILS study). 
Interestingly, in our exploratory analysis examining serum 
CK levels, we found higher peak CK levels in those treated 
with rosuvastatin compared with placebo, though these dif-
ferences did not reach statistical significance. Among those 
with preexisting stage 1 AKI at randomization, rosuvastatin 
treatment is crudely associated with a nearly 3-fold increased 
odds of having peak CK above 10 times upper limit of nor-
mal, though this association again did not reach statistical 
significance, likely owing to the small sample of patients 
with preexisting AKI available for analysis. Based on our 
data, we cannot definitively conclude, nor rule out, that rhab-
domyolysis (or subclinical levels of rhabdomyolysis) played 
a role in the association between rosuvastatin and worsening 
of AKI. There is indeed additional recent literature suggest-
ing acute nephrotoxicity associated with high-potency 
statins,22,23 with one case report of suspected direct tubular 
toxicity associated with high-dose rosuvastatin.22
Our study has the following limitations. First, we did not 
use urine output to define AKI,24 and creatinine measure-
ments were not obtained daily for the entire 28-day treatment 
period. Second, no prehospitalization serum creatinine val-
ues were available. However, as part of the study protocol, 
all creatinine values from the 96 hours prior to randomiza-
tion were systematically collected, and we used the lowest 
creatinine in the prerandomization period as reference. In 
addition, our current analysis may have been underpowered 
to detect significant differences in AKI outcomes, given our 
Table 3. Serum CK Levels.
Subgroup without preexisting AKI at 
randomization (n = 511) Placebo (n = 257) Rosuvastatin (n = 254) P
Baseline CKa 201 ± 291 212 ± 405 .73
Peak CKa 477 ± 1463 1070 ± 10141 .33
Peak CK > 10 times upper limit of normal 11 (4.3%) 15 (5.9%) .40
Subgroup with preexisting stage 1 AKI at 
randomization (n = 93) Placebo (n = 39) Rosuvastatin (n = 54) P
Baseline CKa 389 ± 918 237 ± 566 0.33
Peak CKa 754 ± 1676 3119 ± 15,474 0.35
Peak CK > 10 times upper limit of normal 3 (8%) 11 (20%) 0.09
Note. CK = creatine kinase.
aExpressed as mean ± standard deviation, in U/L.
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fixed sample size from the original SAILS trial. For exam-
ple, we had an 80% power to detect a 12% difference in rate 
of de novo AKI among the 511 patients without preexisting 
AKI, and therefore a smaller effect size of rosuvastatin on 
AKI risk would not have been identified. Finally, given the 
requirement for sepsis-associated ARDS, the SAILS partici-
pants are critically ill with a mean APACHE III score of 93. 
Therefore, the results here may not be generalizable to all 
cases of sepsis-induced AKI. Nevertheless, this study is 
strengthened by randomized and protocoled exposure to 
rosuvastatin, and its completeness of prospectively collected 
data including severity of illness, fluid balance, vasopressor 
use, and preenrollment creatinine values. We also performed 
a thorough analysis adjusting serum creatinine for cumula-
tive fluid balance, as fluid overload is common in this popu-
lation and is known to influence AKI ascertainment.
Conclusions
In conclusion, we demonstrated that rosuvastatin treatment 
in critically ill patients with sepsis and ARDS did not prevent 
de novo AKI and did not prevent worsening of AKI in those 
with preexisting mild AKI. While statins have been proposed 
to be renoprotective in other settings, our study showed no 
renal benefit in sepsis-associated AKI, and potential harm of 
statin administration on exacerbating preexisting mild AKI 
cannot be ruled out.
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